# OnCo record paper-transcend-miller-nejm-2026 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-transcend-miller-nejm-2026/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-transcend-miller-nejm-2026" ;
  schema:name "Setmelanotide for the treatment of acquired hypothalamic obesity (TRANSCEND)"@en ;
  schema:description "In children and adults whose severe weight gain followed damage to the hypothalamus, a year of daily setmelanotide injections cut body-mass index by 16.5 percent while placebo recipients gained 3.3 percent, and hunger fell more too."@en ;
  schema:url <https://onco.cc/key-papers/paper-transcend-miller-nejm-2026/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa2512275>, <https://pubmed.ncbi.nlm.nih.gov/42418774/>, <https://clinicaltrials.gov/study/NCT05774756> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa2512275> ;
  schema:datePublished "2026"^^xsd:gYear ;
  schema:author "Miller JL, van Santen HM, Phillips SA, et al." ;
  onco:cancers <https://onco.cc/cancers/craniopharyngioma/> ;
  onco:sections <https://onco.cc/fronts/supportive-care/> ;
  onco:drugs <https://onco.cc/drugs/setmelanotide/> ;
  onco:companies <https://onco.cc/companies/rhythm-pharmaceuticals/> ;
  onco:trials <https://onco.cc/trials/transcend/> ;
  onco:journals <https://onco.cc/journals/nejm/> .